Global HER 2 Testing Market size was valued at USD 136.04 Mn in 2022 and is expected to reach USD 221.32 Mn by 2029, at a CAGR of 7.2 %.Global Market Overview
HER2 is the Human Epidermal Growth Factor Receptor2. It is the gene that makes a protein rest on the surface of all breast cells. HER2 testing is used to determine whether the cancer cells have too many copies of the HER2 gene or higher than the normal level of the HER2 protein. This testing also determines whether the patient has benefited from the treatment which is designed to target HER2 proteins or genes. HER testing is done on a tissue sample taken while the procedure is called a biopsy. This sample is sent to the laboratory for analyzing the tissue by a pathologist. HER2 testing is frequently used for molecular abnormality in gastric and gastroesophageal cancer. The bottom-up approach was used to estimate the HER 2 testing market size. The market revenue is determined by the primary and secondary data collection methods. For a deeper knowledge of HER 2 testing market penetration, competitive structure, pricing and demand analysis are included in the report. The market report focuses on the drivers, challenges and major restraints of the HER 2 testing industry.To know about the Research Methodology :- Request Free Sample Report
HER 2 Testing Market Dynamics:
Increasing Prevalence of Breast and Gastric Cancer to boosts the market growth
Breast cancer is the most common cancer diagnosed in women. The late age for marriage, first childbirth and menopause are the strong causes of breast cancer. The lack of breast tissue differentiation is due to the late age of marriage and childbirth and more exposure to nonestrogenic mutagens and genotoxicity by estrogen. The exposure to estrogen is prolonged after menopause. The particular inherited high penetrance gene mutations increase the risk of breast cancer. Women found that several mutations such as BRCA1, BRCA2 and PALB-2 in these major genes have been creating risk reduction strategies including surgical removal of both breasts. Gastric Cancer is caused by the infection of the bacterium helicobacter pylori and autoimmune gastritis, it occurs when the immune system of the person attacks the lining of the stomach. It is also caused by tobacco, obesity and radiation. The risk of the development of gastric cancer from birth to the age of 74 is 1.87 percent in males and 0.79 % in females globally. Gastric cancer was the most common cause of cancer-related mortality. Gastric cancer accounts for 783,000 deaths per year and it is the most deadly cancer among males.Technological advancements in the HER 2 testing to fuel the market growth
Technological advancements in imaging improve screening and early detection. The HER2 testing to target trastuzumab treatment for patients associated with breast cancer offers advanced testing technologies in clinical practices. HER2 testing has been developing to determine that patients have breast cancers that overexpress the gene HER2 and the treatment with trastuzumab in 20-30 % of patients is highly effective. HER2 testing is a successful use of testing to target cancer treatment that has been used in clinical practice. Metastatic HER2 the positive breast cancer patients are achieving high survival rates compared to the treatment of anti-HER2 therapies than patients associated with HER2-negative disease. The double HER2 blockade with pertuzumab and trastuzumab mixture with a taxane attained unprecedented survival over the 57 months in the patient’s first line. All the technological advancements in HER2 testing fuel the market growth.HER 2 testing Market Restraints
High cost of the HER 2 testing: The middle class, as well as lower class people, has not affordable for the HER 2 testing due to its high cost. Advanced HER 2 testing such as trastuzumab has a high cost (Can$50000 per year). Trastuzumab costs $49,915 and $28,350 per patient treated in adjuvant and metastatic breast cancer settings. The high cost of Trastuzumab treatments has significant economic burdens on the provincial health budgets in the world.HER 2 testing Market Regional Insights
North America held the HER 2 testing Market in 2022 with the largest market share and is expected to continue its dominance over the forecast period. The regional market is driven by the increasing incidences of the cancers such as breast, stomach, etc., well-established healthcare infrastructure and rising spending on the healthcare sector. The North Central Cancer Treatment Group (NCCTG) Intergroup trial N9831 is the clinical trial which conducted by the breast cancer intergroup. This intergroup evaluate trastuzumab as adjuvant therapy for patients with HER2-positive amputated early breast cancer. The group improves the cure rates and reduces morbidity in women with breast cancer by developing biologically rational combinations of systematic therapies and it also improves the life quality of women with metastatic breast cancer by developing improved regimens incorporating novel agents. Asia Pacific is expected to have significant growth for the HER 2 testing Market over the forecast period. In Asia Pacific, high incidences of gastric and gastroesophageal junction cancer lead to an increase in the demand for HER2 testing. HER2-targeted therapy improves the quality of life for patients with HER2-positive advanced disease and increases the need for high-quality testing procedures to identify patients who have responded to the treatment. The innovation of the scientific capacity program is developed in the region to improve the breast cancer diagnostic tool. The incidence of cancer is increasing rapidly in Western countries due to changes in lifestyle and diet. HER2-positive cancer, which affects about one in five people with breast or gastric cancer and is treated with trastuzumab.HER 2 testing Market Segment Analysis
Based on Technique
On the basis of the technique, the market is categorized into Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC), Chromogenic in situ hybridization (CISH) and Silver-enhanced in situ hybridization. The fluorescence in situ hybridization (FISH) segment dominated the market in 2022 and is expected to grow significantly for the market. Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique that permits the localization of a specific DNA sequence or an entire chromosome in a cell. It is also used for gene mapping, genetic disease diagnosis, and novel oncogenes identification. The FISH technique is the less time-consuming technique as compared to the other conventional technique. In breast cancer, the FISH test is used to measure the amount of HER2/neu gene in each cancer cell and is the most prominent useful technique. The FISH technique is highly accurate and its ability to detect genomic abnormalities in non-viable and non-dividing tissues increases resolution and high turnaround time.On the basis of the cancer type, the market is segmented into Breast Cancer, Gastric Cancer, Bladder cancer and Ovarian cancer. Breast cancer is expected to have the highest growth rate for the HER 2 testing Market during the forecast period. Getting older, genetic mutations, reproductive history, having dense breasts and personal history and family of breast cancer and exposure to the drug are the risk factors that are responsible to increase the incidences of breast cancer. In breast cancer, HER3 genes mutate and make extra copies of genes. HER2 testing is used to detect whether the cancer is HER-2 positive and is also used to see whether the cancer is responding to treatment or returning after treatment.
Based on Cancer Type
Based on the End users, the market is categorized into Hospitals, Diagnostic Laboratories, Specialty Clinics and Others. The Hospitals lead the market in 2022 and are expected to grow significantly for the market. In hospitals, doctors largely used this test to determine whether the cancer cells have too many copies of the HER2 gene or cancers with highest than normal levels of the HER2 protein. Invasive breast cancers are tested for HER2 levels and this is done in the laboratory of hospitals on a sample of breast cancer tissue removed while surgery or biopsy. The hospitals have advanced medical equipment rather than diagnostic laboratories. The Fluorescence in situ hybridization (FISH) machines are a high requirement for the HER 2 testing and are available easily in hospitals. Thus hospitals are the more dominant segment for the HER 2 testing market.
Based on End-User
Competitive Landscape
The Competitive Landscape of the HER 2 testing market covers the number of key companies, company size, their strengths, weaknesses, barriers and threats. It also focuses on the power of the company’s competitive rivals, potential, new market entrants, customers, suppliers and substitute products that drive the profitability of the companies in the HER 2 testing industry. The global HER 2 testing markets include several market players at the country, regional and global levels. Some of the key companies in the HER 2 testing industry Abbot, hoffmann-la roche, Agilent Technologies,Inc., Thermo Fisher Scientific Inc., Empire Genomics Inc.(Bio care Medical LLC), Abnova Corporation, Oxford Gene Technology IP Limited and others. HER 2 testing Market key players have adopted many strategies such as mergers and acquisition collaboration, agreements and geographical expansion pricing investments and expansion of the product portfolio, for the enhancement of the HER2 testing industry. These companies also focus to increase their research and development activities about their HER 2 testing therapy. They have been introducing and innovating some advancements in this therapy to expand their product portfolio. Roche receives FDA approval for the first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu The PATHWAY anti-HER2 (4B5) test is the only FDA-approved companion diagnostic illustrated as an aid in the assessment of HER2 low status in metastatic breast cancer patients. These patients consider Enhertu as a treatment option based on the results of the Phase 3 DESTINY-Breast04 trial.HER 2 testing Market Scope: Inquire before buying
HER 2 testing Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: USD 136.04 Mn Forecast Period 2023 to 2029 CAGR: 7.2 % Market Size in 2029: USD 221.32 Mn Segments Covered: by Product 1. Fluorescence in situ hybridization(FISH) 2. Immunohistochemistry (IHC) 3. Chromogenic in situ hybridization (CISH) 4. Silver-enhanced in situ hybridization by Cancer Type 1. Breast Cancer 2. Gastric Cancer 3. Bladder cancer 4. Ovarian cancer by End-Users 1. Hospitals 2. Diagnostic Laboratories 3. Specialty Clinics 4. Others HER 2 testing Key Players
1. Abbot 2. Roche 3. Agilent Technologies,Inc. 4. Thermo Fisher Scientific Inc. 5. Empire Genomics Inc.(Bio care Medical LLC) 6. Abnova Corporation 7. Oxford Gene Technology IP limited 8. BCRF 9. Genetech 10. Genemed Technologies Inc. 11. PERKINELMER Inc. 12. QIAGEN 13. BioDot 14. BioGenex (U.S)HER 2 testing Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and the Rest of APAC) South America (Brazil, Argentina Rest of South America) Middle East & Africa (South Africa, GCC, Egypt, Nigeria and the Rest of ME&A) Frequently Asked Questions: 1] What is the growth rate of the Global HER 2 testing Market? Ans. The Global HER 2 testing Market is growing at a significant rate of 7.2 % during the forecast period. 2] Which region is expected to dominate the Global HER 2 testing Market? Ans. North America is expected to dominate the HER 2 testing Market during the forecast period. 3] What is the expected Global HER 2 testing Market size by 2029? Ans. The HER 2 testing Market size is expected to reach USD 221.32 Mn by 2029. 4] Which are the top players in the Global HER 2 testing Market? Ans. The major top players in the Global HER 2 testing Market are Abbot,Roche, Agilent Technologies,Inc., Thermo Fisher Scientific Inc., Empire Genomics Inc.(Bio care Medical LLC), Abnova Corporation, Oxford Gene Technology IP limited and others 5] What are the factors driving the Global HER 2 testing Market growth? Ans. The increasing prevalence of breast and gastric cancer technological advancements in HER2 testing are expected to drive market growth during the forecast period.
1. HER 2 Testing Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. HER 2 Testing Market: Dynamics 2.1. HER 2 Testing Market Trends by Region 2.1.1. North America HER 2 Testing Market Trends 2.1.2. Europe HER 2 Testing Market Trends 2.1.3. Asia Pacific HER 2 Testing Market Trends 2.1.4. Middle East and Africa HER 2 Testing Market Trends 2.1.5. South America HER 2 Testing Market Trends 2.2. HER 2 Testing Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America HER 2 Testing Market Drivers 2.2.1.2. North America HER 2 Testing Market Restraints 2.2.1.3. North America HER 2 Testing Market Opportunities 2.2.1.4. North America HER 2 Testing Market Challenges 2.2.2. Europe 2.2.2.1. Europe HER 2 Testing Market Drivers 2.2.2.2. Europe HER 2 Testing Market Restraints 2.2.2.3. Europe HER 2 Testing Market Opportunities 2.2.2.4. Europe HER 2 Testing Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific HER 2 Testing Market Drivers 2.2.3.2. Asia Pacific HER 2 Testing Market Restraints 2.2.3.3. Asia Pacific HER 2 Testing Market Opportunities 2.2.3.4. Asia Pacific HER 2 Testing Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa HER 2 Testing Market Drivers 2.2.4.2. Middle East and Africa HER 2 Testing Market Restraints 2.2.4.3. Middle East and Africa HER 2 Testing Market Opportunities 2.2.4.4. Middle East and Africa HER 2 Testing Market Challenges 2.2.5. South America 2.2.5.1. South America HER 2 Testing Market Drivers 2.2.5.2. South America HER 2 Testing Market Restraints 2.2.5.3. South America HER 2 Testing Market Opportunities 2.2.5.4. South America HER 2 Testing Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For HER 2 Testing Industry 2.8. Analysis of Government Schemes and Initiatives For HER 2 Testing Industry 2.9. HER 2 Testing Market Trade Analysis 2.10. The Global Pandemic Impact on HER 2 Testing Market 3. HER 2 Testing Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. HER 2 Testing Market Size and Forecast, by Product (2022-2029) 3.1.1. Fluorescence in situ hybridization(FISH) 3.1.2. Immunohistochemistry (IHC) 3.1.3. Chromogenic in situ hybridization (CISH) 3.1.4. Silver-enhanced in situ hybridization 3.2. HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 3.2.1. Breast Cancer 3.2.2. Gastric Cancer 3.2.3. Bladder cancer 3.2.4. Ovarian cancer 3.3. HER 2 Testing Market Size and Forecast, by End User (2022-2029) 3.3.1. Hospitals 3.3.2. Diagnostic Laboratories 3.3.3. Specialty Clinics 3.3.4. Others 3.4. HER 2 Testing Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America HER 2 Testing Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America HER 2 Testing Market Size and Forecast, by Product (2022-2029) 4.1.1. Fluorescence in situ hybridization(FISH) 4.1.2. Immunohistochemistry (IHC) 4.1.3. Chromogenic in situ hybridization (CISH) 4.1.4. Silver-enhanced in situ hybridization 4.2. North America HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 4.2.1. Breast Cancer 4.2.2. Gastric Cancer 4.2.3. Bladder cancer 4.2.4. Ovarian cancer 4.3. North America HER 2 Testing Market Size and Forecast, by End User (2022-2029) 4.3.1. Hospitals 4.3.2. Diagnostic Laboratories 4.3.3. Specialty Clinics 4.3.4. Others 4.4. North America HER 2 Testing Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States HER 2 Testing Market Size and Forecast, by Product (2022-2029) 4.4.1.1.1. Fluorescence in situ hybridization(FISH) 4.4.1.1.2. Immunohistochemistry (IHC) 4.4.1.1.3. Chromogenic in situ hybridization (CISH) 4.4.1.1.4. Silver-enhanced in situ hybridization 4.4.1.2. United States HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 4.4.1.2.1. Breast Cancer 4.4.1.2.2. Gastric Cancer 4.4.1.2.3. Bladder cancer 4.4.1.2.4. Ovarian cancer 4.4.1.3. United States HER 2 Testing Market Size and Forecast, by End User (2022-2029) 4.4.1.3.1. Hospitals 4.4.1.3.2. Diagnostic Laboratories 4.4.1.3.3. Specialty Clinics 4.4.1.3.4. Others 4.4.2. Canada 4.4.2.1. Canada HER 2 Testing Market Size and Forecast, by Product (2022-2029) 4.4.2.1.1. Fluorescence in situ hybridization(FISH) 4.4.2.1.2. Immunohistochemistry (IHC) 4.4.2.1.3. Chromogenic in situ hybridization (CISH) 4.4.2.1.4. Silver-enhanced in situ hybridization 4.4.2.2. Canada HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 4.4.2.2.1. Breast Cancer 4.4.2.2.2. Gastric Cancer 4.4.2.2.3. Bladder cancer 4.4.2.2.4. Ovarian cancer 4.4.2.3. Canada HER 2 Testing Market Size and Forecast, by End User (2022-2029) 4.4.2.3.1. Hospitals 4.4.2.3.2. Diagnostic Laboratories 4.4.2.3.3. Specialty Clinics 4.4.2.3.4. Others 4.4.3. Mexico 4.4.3.1. Mexico HER 2 Testing Market Size and Forecast, by Product (2022-2029) 4.4.3.1.1. Fluorescence in situ hybridization(FISH) 4.4.3.1.2. Immunohistochemistry (IHC) 4.4.3.1.3. Chromogenic in situ hybridization (CISH) 4.4.3.1.4. Silver-enhanced in situ hybridization 4.4.3.2. Mexico HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 4.4.3.2.1. Breast Cancer 4.4.3.2.2. Gastric Cancer 4.4.3.2.3. Bladder cancer 4.4.3.2.4. Ovarian cancer 4.4.3.3. Mexico HER 2 Testing Market Size and Forecast, by End User (2022-2029) 4.4.3.3.1. Hospitals 4.4.3.3.2. Diagnostic Laboratories 4.4.3.3.3. Specialty Clinics 4.4.3.3.4. Others 5. Europe HER 2 Testing Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.2. Europe HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.3. Europe HER 2 Testing Market Size and Forecast, by End User (2022-2029) 5.4. Europe HER 2 Testing Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.1.2. United Kingdom HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.1.3. United Kingdom HER 2 Testing Market Size and Forecast, by End User(2022-2029) 5.4.2. France 5.4.2.1. France HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.2.2. France HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.2.3. France HER 2 Testing Market Size and Forecast, by End User(2022-2029) 5.4.3. Germany 5.4.3.1. Germany HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.3.2. Germany HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.3.3. Germany HER 2 Testing Market Size and Forecast, by End User (2022-2029) 5.4.4. Italy 5.4.4.1. Italy HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.4.2. Italy HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.4.3. Italy HER 2 Testing Market Size and Forecast, by End User(2022-2029) 5.4.5. Spain 5.4.5.1. Spain HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.5.2. Spain HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.5.3. Spain HER 2 Testing Market Size and Forecast, by End User (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.6.2. Sweden HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.6.3. Sweden HER 2 Testing Market Size and Forecast, by End User (2022-2029) 5.4.7. Austria 5.4.7.1. Austria HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.7.2. Austria HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.7.3. Austria HER 2 Testing Market Size and Forecast, by End User (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe HER 2 Testing Market Size and Forecast, by Product (2022-2029) 5.4.8.2. Rest of Europe HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 5.4.8.3. Rest of Europe HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6. Asia Pacific HER 2 Testing Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.2. Asia Pacific HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.3. Asia Pacific HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4. Asia Pacific HER 2 Testing Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.1.2. China HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.1.3. China HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.2.2. S Korea HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.2.3. S Korea HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.3. Japan 6.4.3.1. Japan HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.3.2. Japan HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.3.3. Japan HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.4. India 6.4.4.1. India HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.4.2. India HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.4.3. India HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.5. Australia 6.4.5.1. Australia HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.5.2. Australia HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.5.3. Australia HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.6.2. Indonesia HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.6.3. Indonesia HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.7.2. Malaysia HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.7.3. Malaysia HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.8.2. Vietnam HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.8.3. Vietnam HER 2 Testing Market Size and Forecast, by End User(2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.9.2. Taiwan HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.9.3. Taiwan HER 2 Testing Market Size and Forecast, by End User (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific HER 2 Testing Market Size and Forecast, by Product (2022-2029) 6.4.10.2. Rest of Asia Pacific HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 6.4.10.3. Rest of Asia Pacific HER 2 Testing Market Size and Forecast, by End User (2022-2029) 7. Middle East and Africa HER 2 Testing Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa HER 2 Testing Market Size and Forecast, by Product (2022-2029) 7.2. Middle East and Africa HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 7.3. Middle East and Africa HER 2 Testing Market Size and Forecast, by End User (2022-2029) 7.4. Middle East and Africa HER 2 Testing Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa HER 2 Testing Market Size and Forecast, by Product (2022-2029) 7.4.1.2. South Africa HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 7.4.1.3. South Africa HER 2 Testing Market Size and Forecast, by End User (2022-2029) 7.4.2. GCC 7.4.2.1. GCC HER 2 Testing Market Size and Forecast, by Product (2022-2029) 7.4.2.2. GCC HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 7.4.2.3. GCC HER 2 Testing Market Size and Forecast, by End User (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria HER 2 Testing Market Size and Forecast, by Product (2022-2029) 7.4.3.2. Nigeria HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 7.4.3.3. Nigeria HER 2 Testing Market Size and Forecast, by End User (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A HER 2 Testing Market Size and Forecast, by Product (2022-2029) 7.4.4.2. Rest of ME&A HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 7.4.4.3. Rest of ME&A HER 2 Testing Market Size and Forecast, by End User (2022-2029) 8. South America HER 2 Testing Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America HER 2 Testing Market Size and Forecast, by Product (2022-2029) 8.2. South America HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 8.3. South America HER 2 Testing Market Size and Forecast, by End User(2022-2029) 8.4. South America HER 2 Testing Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil HER 2 Testing Market Size and Forecast, by Product (2022-2029) 8.4.1.2. Brazil HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 8.4.1.3. Brazil HER 2 Testing Market Size and Forecast, by End User (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina HER 2 Testing Market Size and Forecast, by Product (2022-2029) 8.4.2.2. Argentina HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 8.4.2.3. Argentina HER 2 Testing Market Size and Forecast, by End User (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America HER 2 Testing Market Size and Forecast, by Product (2022-2029) 8.4.3.2. Rest Of South America HER 2 Testing Market Size and Forecast, by Cancer Types (2022-2029) 8.4.3.3. Rest Of South America HER 2 Testing Market Size and Forecast, by End User (2022-2029) 9. Global HER 2 Testing Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading HER 2 Testing Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Abbot 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Roche 10.3. Agilent Technologies,Inc. 10.4. Thermo Fisher Scientific Inc. 10.5. Empire Genomics Inc.(Bio care Medical LLC) 10.6. Abnova Corporation 10.7. Oxford Gene Technology IP limited 10.8. BCRF 10.9. Genetech 10.10. Genemed Technologies Inc. 10.11. PERKINELMER Inc. 10.12. QIAGEN 10.13. BioDot 10.14. BioGenex (U.S) 11. Key Findings 12. Industry Recommendations 13. HER 2 Testing Market: Research Methodology 14. Terms and Glossary